Literature DB >> 23376458

HLA class I and II alleles are associated with microvascular complications of type 1 diabetes.

E M Lipner1, Y Tomer, J A Noble, M C Monti, J T Lonsdale, B Corso, W C L Stewart, D A Greenberg.   

Abstract

Although HLA alleles are associated with type 1 diabetes, association with microvascular complications remains controversial. We tested HLA association with complications in multiplex type 1 diabetes families. Probands from 425 type 1 diabetes families from the Human Biological Data Interchange (HBDI) collection were analyzed. The frequencies of specific HLA alleles in patients with complications were compared with the frequencies in complications-free patients. The complications we examined were: retinopathy, neuropathy, and nephropathy. We used logistic regression models with covariates to estimate odds ratios. We found that the DRB1*03:01 allele is a protective factor for complications (OR=0.58; p=0.03), as is the DQA1*05:01-DQB1*02:01 haplotype found in linkage disequilibrium with DRB1*03:01 (OR=0.59; p=0.031). The DRB1*04:01 allele showed no evidence of association (OR=1.13; p=0.624), although DRB1*04:01 showed suggestive evidence when the carriers of the protective DRB1*03:01 were removed from the analysis. The class II DQA1*03:01-DQB1*03:02 haplotype was not associated with complications, but the class I allele B*39:06 (OR=3.27; p=0.008) suggested a strong positive association with complications. Our results show that in type 1 diabetes patients, specific HLA alleles may be involved in susceptibility to, or protection from, microvascular complications.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376458      PMCID: PMC3686564          DOI: 10.1016/j.humimm.2013.01.013

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  50 in total

1.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.

Authors:  E R Seaquist; F C Goetz; S Rich; J Barbosa
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

2.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

3.  HLA-DR genotypes influence age at disease onset in children and juveniles with type 1 diabetes mellitus.

Authors:  W L Awa; B O Boehm; T Kapellen; B Rami; P Rupprath; W Marg; M Becker; R W Holl
Journal:  Eur J Endocrinol       Date:  2010-04-06       Impact factor: 6.664

4.  Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study.

Authors:  M Krolewski; P W Eggers; J H Warram
Journal:  Kidney Int       Date:  1996-12       Impact factor: 10.612

5.  Influence of genetic factors (HLA class II genes, insulin-gene region polymorphisms) and metabolic control on the development of diabetic nephropathy.

Authors:  K S Rønningen; H J Bangstad; D E Undlien; E Thorsby
Journal:  Diabetes Res       Date:  1993

6.  Age-dependent HLA genetic heterogeneity of type 1 insulin-dependent diabetes mellitus.

Authors:  S Caillat-Zucman; H J Garchon; J Timsit; R Assan; C Boitard; I Djilali-Saiah; P Bougnères; J F Bach
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

7.  HLA associations in insulin-dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous population.

Authors:  A Svejgaard; B K Jakobsen; P Platz; L P Ryder; J Nerup; M Christy; K Borch-Johnsen; H H Parving; T Deckert; L Mølsted-Pedersen
Journal:  Tissue Antigens       Date:  1986-10

8.  Risk factors and markers associated with proliferative retinopathy in patients with insulin-dependent diabetes.

Authors:  L C Groop; H Teir; S Koskimies; P H Groop; E Matikainen; E Verkkala; T Scheinin; S Kontiainen; A M Teppo; E M Tolppanen
Journal:  Diabetes       Date:  1986-12       Impact factor: 9.461

9.  HLA genes, islet autoantibodies and residual C-peptide at the clinical onset of type 1 diabetes mellitus and the risk of retinopathy 15 years later.

Authors:  Richard A Jensen; Elisabet Agardh; Ake Lernmark; Soffia Gudbjörnsdottir; Nicholas L Smith; David S Siscovick; Carina Törn
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

10.  How does age at onset influence the outcome of autoimmune diseases?

Authors:  Manuel J Amador-Patarroyo; Alberto Rodriguez-Rodriguez; Gladis Montoya-Ortiz
Journal:  Autoimmune Dis       Date:  2011-12-13
View more
  5 in total

1.  Hub Genes Associated with the Diagnosis of Diabetic Retinopathy.

Authors:  Yanhui Tang; Qi Tang; Haicheng Wei; Pinzhang Hu; Donghua Zou; Rixiong Liang; Yu Ling
Journal:  Int J Gen Med       Date:  2021-05-06

2.  Increasing the power of association studies with affected families, unrelated cases and controls.

Authors:  William C L Stewart; Jane Cerise
Journal:  Front Genet       Date:  2013-10-24       Impact factor: 4.599

3.  Identifying genetic risk loci for diabetic complications and showing evidence for heterogeneity of type 1 diabetes based on complications risk.

Authors:  Nandita Mukhopadhyay; Janelle A Noble; Manika Govil; Mary L Marazita; David A Greenberg
Journal:  PLoS One       Date:  2018-02-14       Impact factor: 3.240

4.  Linkage Analysis of Genomic Regions Contributing to the Expression of Type 1 Diabetes Microvascular Complications and Interaction with HLA.

Authors:  Ettie M Lipner; Yaron Tomer; Janelle A Noble; Maria C Monti; John T Lonsdale; Barbara Corso; David A Greenberg
Journal:  J Diabetes Res       Date:  2015-10-11       Impact factor: 4.011

Review 5.  Update on genetics and diabetic retinopathy.

Authors:  Blake M Hampton; Stephen G Schwartz; Milam A Brantley; Harry W Flynn
Journal:  Clin Ophthalmol       Date:  2015-11-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.